ENTITY
Celltrion

Celltrion (068270 KP)

28
Analysis
Health Care • South Korea
Celltrion, Inc. produces and sells biosimilar products, as well as consignment processing services for other businesses.
more
bullish•Celltrion
•30 Jul 2026 06:55•Broker

Celltrion (068270 KS/Buy)Top-tier performance, yet still undervalued vs. peers

We derived our target price for Celltrion by applying a target EV/EBITDA of 28x to our 12-month forward EBITDA estimate of W2.29tr.

Logo
125 Views
Share
bullish•Celltrion Inc
•08 Jan 2026 08:05•Broker

Celltrion (068270 KS/Buy)Consensus Miss Unlikely to Be Repeated This Year

We derived our target price for Celltrion by applying a target EV/EBITDA of 30x to our 12- month forward EBITDA estimate of W1.97tr.

Logo
235 Views
Share
bullish•Celltrion Inc
•06 Nov 2025 19:34•Broker

Celltrion (068270 KS/Buy)Cost Ratio Continues to Improve

Our target price for Celltrion is based on our 12-month forward EBITDA estimate of W1.87tr and a target EV/EBITDA of 27x.

Logo
258 Views
Share
x